These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36395610)

  • 1. Metabolic reprogramming of immune cells in pancreatic cancer progression.
    Xiang H; Yang R; Tu J; Xi Y; Yang S; Lv L; Zhai X; Zhu Y; Dong D; Tao X
    Biomed Pharmacother; 2023 Jan; 157():113992. PubMed ID: 36395610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.
    Guo D; Ye L; Wu W; Yu X; Jin K
    Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(6):923-937. PubMed ID: 37021976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
    Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
    Front Immunol; 2021; 12():774103. PubMed ID: 35250965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K signaling-regulated metabolic reprogramming: From mechanism to application.
    Su WY; Tian LY; Guo LP; Huang LQ; Gao WY
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188952. PubMed ID: 37499988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more.
    Hao X; Ren Y; Feng M; Wang Q; Wang Y
    Biomed Pharmacother; 2021 Sep; 141():111798. PubMed ID: 34120068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications.
    Liu Y; Zhao Y; Song H; Li Y; Liu Z; Ye Z; Zhao J; Wu Y; Tang J; Yao M
    Cancer Lett; 2024 Aug; 597():217076. PubMed ID: 38906524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic reprogramming of macrophages during infections and cancer.
    Wang S; Liu R; Yu Q; Dong L; Bi Y; Liu G
    Cancer Lett; 2019 Jun; 452():14-22. PubMed ID: 30905817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes.
    Malayil R; Chhichholiya Y; Vasudeva K; Singh HV; Singh T; Singh S; Munshi A
    Med Oncol; 2023 May; 40(6):174. PubMed ID: 37170010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunometabolism: A new target for improving cancer immunotherapy.
    Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
    Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic regulation of tumor metabolic reprogramming.
    Tarrado-Castellarnau M; de Atauri P; Cascante M
    Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMPK-a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment?
    Wang N; Wang B; Maswikiti EP; Yu Y; Song K; Ma C; Han X; Ma H; Deng X; Yu R; Chen H
    Cell Death Discov; 2024 May; 10(1):237. PubMed ID: 38762523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.
    Niu N; Shen X; Zhang L; Chen Y; Lu P; Yang W; Liu M; Shi J; Xu D; Tang Y; Yang X; Weng Y; Zhao X; Wu LM; Sun Y; Xue J
    Adv Sci (Weinh); 2023 Jan; 10(2):e2202937. PubMed ID: 36453584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
    Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
    Front Immunol; 2019; 10():1399. PubMed ID: 31275326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Reprogramming of Myeloid-derived Suppressor Cells in the Tumor Microenvironment.
    Liu L; Huo S; Liu J; Li Q; Wang J
    Discov Med; 2021; 31(164):141-146. PubMed ID: 35188888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging roles of non-coding RNAs in the metabolic reprogramming of tumor-associated macrophages.
    Li J; Lu Z; Zhang Y; Xia L; Su Z
    Immunol Lett; 2021 Apr; 232():27-34. PubMed ID: 33577913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.